Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. (SNOA): 2 pipeline candidates · ~21 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.3 months
D/E 2.97 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for Sonoma Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.9M
Cash
$2.6M
Quarterly Burn
$764K
Runway
21.3 mo
Revenue
$4.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$131K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 37,574 | $80K |
| geode capital management, llc | 19,941 | $42K |
| morgan stanley | 2,004 | $4K |
| citigroup inc | 1,425 | $3K |
| osaic holdings, inc. | 500 | $1K |
| blackrock, inc. | 113 | $241 |
| vanguard fiduciary trust co | 100 | $213 |
| us bancorp \de\ | 25 | $53 |
| ubs group ag | 6 | $13 |
| quaker wealth management, llc | 3 | $7 |
Showing top 10 of 13 institutional holders of Sonoma Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sonoma Pharmaceuticals, Inc.'s pipeline?
Sonoma Pharmaceuticals, Inc. (SNOA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sonoma Pharmaceuticals, Inc.'s lead drug candidate?
Sonoma Pharmaceuticals, Inc.'s most advanced tracked candidate is microcyn (Approved) for Wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants.
What is Sonoma Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sonoma Pharmaceuticals, Inc. has approximately 21.3 months of cash runway.
What is Sonoma Pharmaceuticals, Inc.'s market capitalization?
Sonoma Pharmaceuticals, Inc.'s market capitalization is approximately $3.9M.
Who is the CEO of Sonoma Pharmaceuticals, Inc.?
Ms. Amy M. Trombly Esq., J.D. is the chief executive officer of Sonoma Pharmaceuticals, Inc. (SNOA).
Get the full picture on Sonoma Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.